Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention.

Sankaranarayanan R, Valiveti CK, Dachineni R, Kumar DR, Lick T, Bhat GJ.

Mol Med Rep. 2020 Jan;21(1):20-34. doi: 10.3892/mmr.2019.10822. Epub 2019 Nov 18.

2.

The Flavonoid Metabolite 2,4,6-Trihydroxybenzoic Acid Is a CDK Inhibitor and an Anti-Proliferative Agent: A Potential Role in Cancer Prevention.

Sankaranarayanan R, Valiveti CK, Kumar DR, Van Slambrouck S, Kesharwani SS, Seefeldt T, Scaria J, Tummala H, Bhat GJ.

Cancers (Basel). 2019 Mar 26;11(3). pii: E427. doi: 10.3390/cancers11030427.

3.

Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer.

Dachineni R, Kumar DR, Callegari E, Kesharwani SS, Sankaranarayanan R, Seefeldt T, Tummala H, Bhat GJ.

Int J Oncol. 2017 Dec;51(6):1661-1673. doi: 10.3892/ijo.2017.4167. Epub 2017 Oct 19.

4.

Aspirin inhibits glucose‑6‑phosphate dehydrogenase activity in HCT 116 cells through acetylation: Identification of aspirin-acetylated sites.

Ai G, Dachineni R, Kumar DR, Alfonso LF, Marimuthu S, Bhat GJ.

Mol Med Rep. 2016 Aug;14(2):1726-32. doi: 10.3892/mmr.2016.5449. Epub 2016 Jun 27.

5.

Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention.

Dachineni R, Ai G, Kumar DR, Sadhu SS, Tummala H, Bhat GJ.

Mol Cancer Res. 2016 Mar;14(3):241-52. doi: 10.1158/1541-7786.MCR-15-0360. Epub 2015 Dec 18.

6.

Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53.

Ai G, Dachineni R, Kumar DR, Marimuthu S, Alfonso LF, Bhat GJ.

Tumour Biol. 2016 May;37(5):6007-16. doi: 10.1007/s13277-015-4438-3. Epub 2015 Nov 23.

PMID:
26596838

Supplemental Content

Loading ...
Support Center